DBV Technologies S.A. (EPA:DBV)

Market Cap	110.75M
Revenue (ttm)	4.06M
Net Income (ttm)	-110.02M
Shares Out	102.55M
EPS (ttm)	-1.13
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	10,557,523
Average Volume	1,210,712
Open	0.980
Previous Close	0.781
Day's Range	0.956 - 1.268
52-Week Range	0.506 - 1.480
Beta	0.92
RSI	68.00
Earnings Date	Mar 5, 2025

About DBV Technologies

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis. The company’s earlier stage research programs includes vaccine for the respirato...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Employees: 105
• Stock Exchange: Euronext Paris
• Ticker Symbol: DBV

Financial Performance

In 2024, DBV Technologies's revenue was $4.20 million, a decrease of -73.30% compared to the previous year's $15.73 million. Losses were -$113.90 million, 56.6% more than in 2023.

Financial numbers in USD